Improved Breast Cancer Diagnosis through Transfer Learning on Hematoxylin and Eosin Stained Histology Images

Breast cancer is one of the leading causes of death for women worldwide. Early screening is essential for early identification, but the chance of survival declines as the cancer progresses into advanced stages. For this study, the most recent BRACS dataset of histological (H\&E) stained images was used to classify breast cancer tumours, which contains both the whole-slide images (WSI) and region-of-interest (ROI) images, however, for our study we have considered ROI images. We have experimented using different pre-trained deep learning models, such as Xception, EfficientNet, ResNet50, and InceptionResNet, pre-trained on the ImageNet weights. We pre-processed the BRACS ROI along with image augmentation, upsampling, and dataset split strategies. For the default dataset split, the best results were obtained by ResNet50 achieving 66\% f1-score. For the custom dataset split, the best results were obtained by performing upsampling and image augmentation which results in 96.2\% f1-score. Our second approach also reduced the number of false positive and false negative classifications to less than 3\% for each class. We believe that our study significantly impacts the early diagnosis and identification of breast cancer tumors and their subtypes, especially atypical and malignant tumors, thus improving patient outcomes and reducing patient mortality rates. Overall, this study has primarily focused on identifying seven (7) breast cancer tumor subtypes, and we believe that the experimental models can be fine-tuned further to generalize over previous breast cancer histology datasets as well.Comment: 11 pages, 4 figure

Cancer Health Disparities Drivers with BERTopic Modelling and Pycaret Evaluation

The complex interplay of social, behavioural, lifestyle, environmental, health system, and natural health variables contribute to disparities in cancer treatment across racial and ethnic groups. Consequently, it is necessary to identify the variables contributing to cancer health inequalities and develop strategies to achieve health equality. Pubmed abstract on Cancer health disparities was scraped with a bio.Entrez python package. Preprocessed data with regex and Natural tool kit(NLTK), topic modelling with BERTopic embeddings, and c-TF-IDF to construct dense clusters and analyse top topics linked with Cancer health disparities. Model evaluation with Pycaret coherence score and web app deployment with Streamlit. The results showed that Topic 32 with terms obese, female, male, school, survey, student, post, and discrepancy had the best coherence score of 0.3687. In contrast, topic 8 with terms prevalence, adult, income, high, usage, diabetes, education, elderly, change and low, received the least coherence score of 0.3255. The model classifies each Subject Word score based on the scores, the granular topic concerns and trends related to cancer health disparities, investigates the connection between drivers of cancer health disparities, and evaluates the model with their coherence score values

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication